Follistatin-like 1 and its paralogs in heart development and cardiovascular disease

HOŘÁK, Martin, DeLisa FAIRWEATHER, Piia Pauliina KOKKONEN, David BEDNÁŘ and Julie DOBROVOLNÁ. Follistatin-like 1 and its paralogs in heart development and cardiovascular disease. Heart Failure Reviews. New York: Springer US, 2022, vol. 27, No 6, p. 2251-2265. ISSN 1382-4147. Available from: https://dx.doi.org/10.1007/s10741-022-10262-6.

Basic information

• Original name: Follistatin-like 1 and its paralogs in heart development and cardiovascular disease
• Authors: HOŘÁK, Martin (203 Czech Republic, belonging to the institution), DeLisa FAIRWEATHER, Piia Pauliina KOKKONEN (246 Finland, belonging to the institution), David BEDNÁŘ (203 Czech Republic, belonging to the institution) and Julie DOBROVOLNÁ (203 Czech Republic, guarantor, belonging to the institution).
• Edition: Heart Failure Reviews, New York, Springer US, 2022, 1382-4147.

Other information

• Original language: English
• Type of outcome: Article in a journal
• Field of Study: 30201 Cardiac and Cardiovascular systems
• Country of publisher: Netherlands
• Confidentiality degree: is not subject to a state or trade secret
• WWW: URL
• Impact factor: Impact factor: 4.600
• RIV identification code: RIV/00216224:14310/22:00127632
• Organization unit: Faculty of Science
• Doi: http://dx.doi.org/10.1007/s10741-022-10262-6
• UT WoS: 000828956200001
• Keywords in English: FSTL1; FSTL4; FSTL5; Heart failure; Inflammation
• Tags: 14110518, podil, rivok
• Tags: International impact, Reviewed

Abstract

Cardiovascular diseases (CVDs) are a group of disorders affecting the heart and blood vessels and a leading cause of death worldwide. Thus, there is a need to identify new cardiokines that may protect the heart from damage as reported in GBD 2017 Causes of Death Collaborators (2018) (The Lancet 392:1736-1788). Follistatin-like 1 (FSTL1) is a cardiokine that is highly expressed in the heart and released to the serum after cardiac injury where it is associated with CVD and predicts poor outcome. The action of FSTL1 likely depends not only on the tissue source but also post-translation modifications that are target tissue- and cell-specific. Animal studies examining the effect of FSTL1 in various models of heart disease have exploded over the past 15 years and primarily report a protective effect spanning from inhibiting inflammation via transforming growth factor, preventing remodeling and fibrosis to promoting angiogenesis and hypertrophy. A better understanding of FSTL1 and its homologs is needed to determine whether this protein could be a useful novel biomarker to predict poor outcome and death and whether it has therapeutic potential. The aim of this review is to provide a comprehensive description of the literature for this family of proteins in order to better understand their role in normal physiology and CVD.

Links

• EF15_003/0000469, research and development project: Name: Cetocoen Plus
• EF17_043/0009632, research and development project: Name: CETOCOEN Excellence
• LM2018121, research and development project: Name: Výzkumná infrastruktura RECETOX (Acronym: RECETOX RI)

Investor: Ministry of Education, Youth and Sports of the CR, RECETOX RI

• NU22-02-00418, research and development project: Name: Klinické a proteomické biomarkery predikující reverzní remodelaci levé komory u pacientů s nově zjištěnou dilatační kardiomyopatií

Investor: Ministry of Health of the CR, Subprogram 1 - standard

• 857560, interní kód MU(CEP code: EF17_043/0009632): Name: CETOCOEN Excellence (Acronym: CETOCOEN Excellence)

Investor: European Union, Spreading excellence and widening participation